Comparing of Cocrystal Pharma Inc. (COCP) and scPharmaceuticals Inc. (NASDAQ:SCPH)

Cocrystal Pharma Inc. (NASDAQ:COCP) and scPharmaceuticals Inc. (NASDAQ:SCPH) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cocrystal Pharma Inc. N/A 0.00 N/A 0.04 81.05
scPharmaceuticals Inc. N/A 0.00 31.22M -1.68 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Cocrystal Pharma Inc. and scPharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Cocrystal Pharma Inc. 0.00% 0.4% 0.4%
scPharmaceuticals Inc. 0.00% -33.2% -28.4%

Liquidity

The Current Ratio and a Quick Ratio of Cocrystal Pharma Inc. are 4.4 and 4.4. Competitively, scPharmaceuticals Inc. has 13 and 13 for Current and Quick Ratio. scPharmaceuticals Inc.’s better ability to pay short and long-term obligations than Cocrystal Pharma Inc.

Institutional & Insider Ownership

Roughly 7.2% of Cocrystal Pharma Inc. shares are held by institutional investors while 77.2% of scPharmaceuticals Inc. are owned by institutional investors. 67.67% are Cocrystal Pharma Inc.’s share held by insiders. Comparatively, scPharmaceuticals Inc. has 17.25% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cocrystal Pharma Inc. 12% 6.21% -8.06% -16.93% -23% -14.44%
scPharmaceuticals Inc. 0.62% -16.15% -30.28% -36.13% -79.41% -13.03%

For the past year Cocrystal Pharma Inc. was more bearish than scPharmaceuticals Inc.

Summary

On 5 of the 7 factors Cocrystal Pharma Inc. beats scPharmaceuticals Inc.

Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, focuses on developing antiviral therapeutics for human diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including hepatitis C virus (HCV), influenza virus, and norovirus. The company also develops targeted in-house chemical libraries consisting of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. It has research collaboration agreement with HitGen, Ltd. and InterX, Inc. to develop small molecule drug candidates against several undisclosed targets. Cocrystal Pharma, Inc. was founded in 2007 and is headquartered in Tucker, Georgia.

scPharmaceuticals Inc., biopharmaceutical company, engages in the development and commercialization of transformative pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.